membrane interactions. During cuprophane hemodialysis numerous neutrophil dysfunctions may occur due to activation by complement split-products (C3a, C5a) and/or arachidonic acid metabolites [2, 3, 17] . Sequestration of activated neutrophils into the pulmonary capillaries causes profound systemic leukopenia during the early phase of hemodialysis [3] . Sixty to 120 minutes after initiation of hemodialysis there is a rebound leukocytosis that has been attributed to the return of neutrophils from the lungs into the circulation as well as to bone marrow release of immature neutrophils. Moreover, neutrophils remaining in the peripheral circulation during the cuprophane membrane-related neutropenic phase are functionally altered as compared to predialysis neutrophils in the same patient. The abnormal functional responses include decreased chemotaxis, increased aggregation, increased adherence, and degranulation [6, 12] . Pentoxifylline (1-(5oxohexyl)-3,7 dimethylxanthine) (PTX) has been shown to inhibit several neutrophil functions in vitro, including chemotaxis, oxidant production, and the priming of neutrophils by platelet activating factor (PAF) [1, 7, 19] . PTX in vitro also suppressed the release of endotoxin-induced tumor necrosis factor (TNF) from macrophages [18] . Furthermore, a protective effect of PTX was demonstrated in animal models of endotoxin-induced acute lung injury [8] . These data suggest that the concept of modulation of neutrophil and macrophage function by PTX seems to be an interesting approach in inflammatory diseases. We therefore examined the effects of PTX on hemodialysisrelated neutrophil dysfunctions in a randomized, double-blind, cross-over pilot study. In particular, we were interested in evaluating drug concentrations high enough to protect neutrophils from activation.
Patients and Methods

Patients
The pilot study incuded eight patients (4 females, 4 males; mean age 51 +7 years) with end-stage renal disease, who had been on maintenance hemodialysis for at least three months. Three out of eight patients suffered from diabetic nephropathy, three from chronic glomerulonephritis, and two from chronic interstitial nephritis. None of the patients had a history of allergic reactions or clinical evidence of acute inflammation. None were taking drugs known to affect neutrophil production, function, or kinetics. All patients had normal white blood cell (WBC) and differential cell counts. Routine dialysis techniques were employed and the patients underwent four hours of bicarbonate hemodialysis three times a week. The cuprophane hollow fiber dialyzer from Hospal (Disscap 110 E containing 1.1 m 2 surface) was used. Informed consent was obtained from all paticipating subjects prior to the study,
Study Design and Blood Sampling
The patients were randomly assigned to receive either 400 mg of PTX or matched placebo orally twice a day over 14 days following a two-week washout period in a blind cross-over design. The measurements took place at the end of the placebo or treatment phase during two comparable hemodialysis sessions. In addition, PTX or saline was given as a bolus injection of 100 mg intravenously before dialysis followed by a continuous infusion of 300 mg over 3 hours. WBC, differential, and platelet counts and plasma levels of neutrophil elastase and lactoferrin were investigated. Predialysis blood samples were drawn from the arteriovenous fistula before heparinization. Subsequent samples were taken from the venous line of the dialyzer at 10, 20, 30 and 240 minutes after initiation of hemodialysis. Citrated whole blood was immediately spun down. Plasma aliquots were stored at -80 ~ C until measurement.
Determination of Blood Cells and Neutrophil Proteins
WBC, platelet, and differential counts were determined by an automatic blood cell counter (Sysmex). Plasma levels of both neutrophil elastase in complex with cd proteinase inhibitor and neutrophil lactoferrin were determined employing highly sensitive enzyme-linked immunoassays [15, 16] .
Statistical Analysis
Data are presented as median_+ SEM. Student's ttest for paired data was used to test for statistically significant differences between treatment groups, or for changes within a group. A p-value less than 0.05 was considered significant.
Results
Oral PTX given in doses of 800 mg/day was well tolerated by all patients. However, additional intravenous PTX (400 mg/3 h) induced nausea in three out of eight cases. Six different time intervals were chosen to represent different phases in neutrophil kinetics and functions during the course of cuprophane hemodialysis. Oral PTX treatment (Table 1) did not significantly alter predialytic WBC, neutrophil, and platelet counts as well as plasma levels of neutrophil elastase and lactoferrin.
In the placebo group the WBC count dropped to a minimum of 2900 + 300/gl at 20 minutes (p < 0.0001); thereafter the WBC count showed a steady rise, reaching 3900+900/gl at 30 minutes and 10200 + 1000Atl at 4 hours. Neutrophil counts closely paralleled the changes in WBC counts, whereas lymphocyte counts did not change. PTX treatment neither prevented nor significantly modified the leukopenic response (Fig. I a) .
In the placebo group plasma levels of neutrophil elastase dropped significantly (p <0.01) from 181 +25 ng/ml before dialysis to 141 _+21 ng/ml at 20 minutes. Thereafter, plasma levels of neutrophil elastase increased significantly (p < 0.001) to 322_+ 72 ng/ml at 4 hours. PTX treatment did not exhibit a statistically significant effect on plasma levels of neutrophil elastase during dialysis ( Fig. 1 c) .
Measurements of lactoferrin plasma levels during cuprophane hemodialysis revealed that this neutrophil lysosomal protein was more rapidly released than neutrophil elastase. Lactoferrin plasma levels in the placebo group increased from 220 _+ 28 ng/ml before dialysis to 400 +_ 57 ng/ml at 20 minutes (p<0.003), followed by a further increase to 710+88 ng/ml at the end of the dialysis session. PTX treatment attenuated the increase of lactoferrin in plasma to 460-t-64 ng/ml at 60 minutes (p<0.05) and 430_+74 ng/ml at the end of the hemodialysis session. Compared to the control group, however, this effect was not statistically significant ( Fig. 1 d) . Platelet counts were not significantly altered either during the course of hemodialysis treatment or by the administration of PTX (Fig. 1 b) .
Discussion
Exposure of blood to the cuprophane membrane during clinical hemodialysis caused profound but transient neutropenia and a release of neutrophilderived elastase and lactoferrin in our patients. The time course of elastase plasma levels was paralleled by the initial drop in leukocyte counts. Lactoferrin, however, showed a continuous increase until the end of the hemodialysis treatment. These major results of our investigation provide additional support for the concept that sequestration of primed neutrophils into the microcirculation of the lungs and release of neutrophil components upon stimulation are interlinked pathophysiological mechanisms which play an important role in acute and permanent deterioration of neutrophil functions and neutrophil death during cuprophane hemodialysis [5, 10] . Neutrophil dysfunctions are the measurable consequences of a complex series of activatd pathways including the complement cascade and arachidonic acid metabolism. The clinical relevance of these phenomena and their long-term sequelae are not yet fully unterstood [4] . However, it is likely that cyclic neutropenia and adversely affected neutrophil functions may contribute to the increased infection rate in dialysis patients. The local imbalance of high amounts of released cell proteinases and their extracellularly available proteinase inhibitors may favor the development of pulmonary disease in long-term hemodialysis patients [9] .
PTX has been shown to inhibit several neutrophil functions in vitro after activation by potent stimuli [7] . In our study, conventional doses of oral PTX (800 mg daily) and a continuous infusion of 400 mg during hemodialysis did not exhibit a striking effect on cuprophane membrane-related neu-tropenia and neutrophil degranulation. Furthermore, the bolus injection of 100 mg of PTX before hemodialysis followed by a continuous infusion of 100 mg/h over 3 hours induced nausea in three of eight patients.
The attenuated release of lactoferrin, a lysosomal protein of specific granules, may hint at a proposed mode of PTX action. Unlike elastase of azurophilic granules, lactoferrin is readily released by soluble stimuli (e.g., PAF, C5a, endotoxin) [11] . PTX may therefore have prevented the discharge of specific neutrophil granules at least to some extent in our patients. Our findings are in contrast to the data from in-vitro experiments, but are in agreement with preliminary observations in other studies [13, 14] that showed no striking modification of cuprophane membrane-induced neutropenia by PTX during hemodialysis treatment. This apparent discrepancy between experimental and clinical studies may be explained by differences in the applied drug concentrations. Peak plasma levels after an oral dose of 100 mg of PTX amount to 3 to 5 gmol/1, several active metabolites may reach slightly higher plasma levels [20] . Under invitro conditions, however [7] , neutrophil aggregation and augmentation of their adherence was only modestly inhibited by much higher PTX concentrations (ADso% 1 mmol/1 or ADso% >240 gmol/ 1, respectively). Thus Hammerschmidt et al. [7] considered in vitro drug effects with ADso% > 50 gmol/1 unlikely to be of chlinical importance. On the other hand, Sullivan et al. were able to demonstrate that much lower concentrations of PTX reduced cytokine-induced granulocyte migration [19] . Another recent study showed that conventional doses of PTX reduced endotoxin-induced TNF release in healthy normal subjects [21] . These findings suggest that distinct leukocyte functions may be inhibited at different PTX concentrations. Moreover, the inhibitory effect of PTX may depend on the activating stimulus. We conclude that pretreatment with conventional doses of PTX results in drug concentrations which are not high enough to prevent significantly the neutrophil activation which occurs during cuprophane hemodialysis. 
